Impact of Zanamivir Treatment on Productivity, Health Status and Healthcare Resource Use in Patients with Influenza

This publication has 12 references indexed in Scilit:

• Efficacy and Safety of the Neuraminidase Inhibitor Zanamivirin the Treatment of Influenza A and B Virus Infections
  The Journal of Infectious Diseases, 1999
• A Pharmacoeconomic Model for the Treatment of Influenza
  PharmacoEconomics, 1999
• Influenza
  PharmacoEconomics, 1999
• Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections
  The Lancet, 1998
• Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenzavirus Infections
  New England Journal of Medicine, 1997
• French Economic Evaluations of Influenza and Influenza Vaccination
  PharmacoEconomics, 1996
• Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium
  Antiviral Research, 1994
• 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro
  Antimicrobial Agents and Chemotherapy, 1993
• Selection and Characterization of a Neuraminidase-Minus Mutant of Influenza Virus and Its Rescue by Cloned Neuraminidase Genes
  Virology, 1993
• The Swine-Influenza Decision
  New England Journal of Medicine, 1976